Merrimack Pharmaceuticals Inc. (MACK) had a good day on the market for Tuesday December 03 as shares jumped 9.87% to close at $4.12. About 112,941 shares traded hands on 642 trades for the day, compared with an average daily volume of n/a shares out of a total float of 13.36 million. After opening the trading day at $4.02, shares of Merrimack Pharmaceuticals Inc. stayed within a range of $4.19 to $3.83.
With today’s gains, Merrimack Pharmaceuticals Inc. now has a market cap of $55.06 million. Shares of Merrimack Pharmaceuticals Inc. have been trading within a range of $7.50 and $3.51 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company’s core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.
Merrimack Pharmaceuticals Inc. is based out of Cambridge, MA and has some 27 employees. Its CEO is Gary L. Crocker.
Merrimack Pharmaceuticals Inc. is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
